Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small integral membrane protein 45 (SMIM45) is annotated as a protein-coding gene located on human chromosome 22 and is also known by the non-coding RNA symbol LINC00634[1][4][5][8][11]. The gene encodes at least one ultra-conserved 68-amino acid open reading frame (ORF), possibly with functional significance in neuron maturation, though much about its translation and cellular role remains unresolved[2][8][13]. The gene also contains another ORF (107 aa), which may be uniquely human but lacks clear evidence of translation in most tissues[2]. Due to the overlap with non-coding RNA annotation, the gene is sometimes described as a "long intergenic non-protein coding RNA," and the existing data does not support its consideration as a conventional therapeutic target (e.g., receptor, enzyme, transporter)[1][11]. No credible evidence links SMIM45 to direct drug interactions, use as a biomarker, or specific therapeutic safety concerns. Some literature implicates the LINC00634 transcript as an oncogene in certain cancers, but this refers to RNA-level regulatory mechanisms rather than protein function[11]. The gene is inconsistently classified as both a protein-coding gene and a long non-coding RNA (based on aliases and some database entries)[1][5][11]. There is no evidence that SMIM45 is a well-recognized therapeutic target (e.g., classic druggable receptor, enzyme, transporter, or ion channel), nor is it commonly referenced as such in drug discovery or pharmacology resources. Reported biological functions and disease connections are preliminary, mostly limited to transcript-level roles (e.g., in cancer, where the LINC00634 RNA is involved in regulatory networks)[11]. SMIM45 is not a conventional therapeutic target and is not currently considered druggable. Its gene structure and function remain partially characterized, and much of its reported biological significance relates to its RNA rather than as a classical protein target.
None established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small integral membrane protein 45 (SMIM45).